ALXN-2030
- Generic Name
- ALXN-2030
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Phase 2
Recruiting
- Conditions
- Antibody-Mediated RejectionKidney TransplantationBiopsy-proven Histologic ScoresAMR
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06744647
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05501717
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath